These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 8305843)
21. Glomerular mesangial fibrillary deposits in a patient with diabetes mellitus. Gonul II; Gough J; Jim K; Benediktsson H Int Urol Nephrol; 2006; 38(3-4):767-72. PubMed ID: 17211574 [TBL] [Abstract][Full Text] [Related]
22. Role of mesangial expansion in the pathogenesis of diabetic nephropathy. Dalla Vestra M; Saller A; Mauer M; Fioretto P J Nephrol; 2001; 14 Suppl 4():S51-7. PubMed ID: 11798146 [TBL] [Abstract][Full Text] [Related]
30. Smad1 as a biomarker for diabetic nephropathy. Kato H; Si H; Hostetter T; Susztak K Diabetes; 2008 Jun; 57(6):1459-60. PubMed ID: 18511448 [No Abstract] [Full Text] [Related]
31. Localization of fibril/microfibril and basement membrane collagens in diabetic glomerulosclerosis in type 2 diabetes. Makino H; Shikata K; Wieslander J; Wada J; Kashihara N; Yoshioka K; Ota Z Diabet Med; 1994 Apr; 11(3):304-11. PubMed ID: 8033531 [TBL] [Abstract][Full Text] [Related]
32. Kinetic study of glomerular cells of diabetic rats in relation to the development of irreversible glomerular sclerosis. Osawa G; Sasaki T; Sato T; Yamada M; Kitano Y J Diabet Complications; 1991; 5(2-3):115-7. PubMed ID: 1770014 [TBL] [Abstract][Full Text] [Related]
33. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats. Itagaki I; Shimizu K; Kamanaka Y; Ebata K; Kikkawa R; Haneda M; Shigeta Y Diabetes Res Clin Pract; 1994 Oct; 25(3):147-54. PubMed ID: 7851268 [TBL] [Abstract][Full Text] [Related]
34. Diabetic kidney disease in the db/db mouse. Sharma K; McCue P; Dunn SR Am J Physiol Renal Physiol; 2003 Jun; 284(6):F1138-44. PubMed ID: 12736165 [TBL] [Abstract][Full Text] [Related]
35. The contribution of mesangial cell collagen synthesis to the pathogenesis of diabetic nephropathy. Kashgarian M; Oshima S; Takeuchi A; Throckmorton D; Rasmussen H Contrib Nephrol; 1994; 107():132-9. PubMed ID: 8004959 [No Abstract] [Full Text] [Related]
36. Mesangial cell dysfunction as a pathogenesis of diabetic nephropathy. Haneda M; Koya D; Kikkawa R Contrib Nephrol; 2001; (134):16-29. PubMed ID: 11665284 [No Abstract] [Full Text] [Related]
37. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy. Mizuno S; Nakamura T Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594 [TBL] [Abstract][Full Text] [Related]
38. Molecular biology of diabetic glomerulosclerosis. Del Prete D; Anglani F; Ceol M; D'Angelo A; Forino M; Vianello D; Baggio B; Gambaro G Nephrol Dial Transplant; 1998; 13 Suppl 8():20-5. PubMed ID: 9870421 [TBL] [Abstract][Full Text] [Related]
39. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice. Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011 [TBL] [Abstract][Full Text] [Related]
40. Henoch-Schönlein purpura in a patient with diabetic nephropathy: case report and a review of the literature. Padilla B; Weiss M; Kant KS Am J Kidney Dis; 1992 Aug; 20(2):191-4. PubMed ID: 1496976 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]